Open Access Opinion Article ID: JCMC-7-222

    Are ACE inhibitors and ARBs more beneficial than harmful in the treatment of severe COVID-19 disease?

    Christian A Devaux*

    After starting in China four months ago, the COVID-19 pandemic now affects most countries and has already caused more than 200,000 deaths by April 26, 2020

    Under chest computerized tomography scans, the majority of severe COVID-19 patients show bilateral ground glass-like opacities and subsegmental areas of consolidation indicative of pneumonia. If in its severe forms this disease affects the lungs, in many cases it is also responsible for a multi-organ failure with adverse myocardial remodeling, myocardial stress, and cardiomyopathy [1,2]. 


    Published on: May 5, 2020 Pages: 101-103

    Full Text PDF Full Text HTML DOI: 10.17352/2455-2976.000122
    CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat


    Global Views

    Case Reports

    Peertechz Tweets

    Pinterest on JCMC

    Help ? Google Reviews 11